|
|
Volumn 7, Issue , 2008, Pages 3-
|
|
Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.
a
a
Research Unit
(Spain)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
ARYLDIALKYLPHOSPHATASE;
ARYLESTERASE;
CARBOXYLESTERASE;
CD36 ANTIGEN;
LIPID;
LIPID PEROXIDE;
LOSARTAN;
NFE2L2 PROTEIN, MOUSE;
ROSIGLITAZONE;
TRANSCRIPTION FACTOR NRF2;
UNCLASSIFIED DRUG;
ANIMAL;
ARTICLE;
ATHEROSCLEROSIS;
BLOOD;
C57BL MOUSE;
CHOLESTEROL INTAKE;
GENE EXPRESSION REGULATION;
GENETICS;
LIPID PEROXIDATION;
MOUSE;
PHYSIOLOGY;
UPREGULATION;
ANIMALS;
ANTIGENS, CD36;
ARYLDIALKYLPHOSPHATASE;
ATHEROSCLEROSIS;
CARBOXYLIC ESTER HYDROLASES;
CHOLESTEROL, DIETARY;
GENE EXPRESSION REGULATION;
LIPID PEROXIDATION;
LIPID PEROXIDES;
LIPIDS;
LOSARTAN;
MICE;
MICE, INBRED C57BL;
NF-E2-RELATED FACTOR 2;
THIAZOLIDINEDIONES;
UP-REGULATION;
|
|
EID: 41149089663
PISSN: None
EISSN: 14752840
Source Type: Journal
DOI: 10.1186/1475-2840-7-3 Document Type: Article |
|
Times cited : (13)
|
|
References (0)
|
